CY2256B1 - Apolipoprotein-b synthesis inhibitors - Google Patents
Apolipoprotein-b synthesis inhibitorsInfo
- Publication number
- CY2256B1 CY2256B1 CY0200004A CY0200004A CY2256B1 CY 2256 B1 CY2256 B1 CY 2256B1 CY 0200004 A CY0200004 A CY 0200004A CY 0200004 A CY0200004 A CY 0200004A CY 2256 B1 CY2256 B1 CY 2256B1
- Authority
- CY
- Cyprus
- Prior art keywords
- apolipoprotein
- synthesis inhibitors
- inhibitors
- synthesis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP94203120 | 1994-10-27 | ||
| US08/455,304 US5521186A (en) | 1994-10-27 | 1995-05-31 | Apolipoprotein-β synthesis inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY2256B1 true CY2256B1 (en) | 2003-07-04 |
Family
ID=26136684
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY0200004A CY2256B1 (en) | 1994-10-27 | 2002-01-04 | Apolipoprotein-b synthesis inhibitors |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US5929075A (hu) |
| EP (1) | EP0788496B1 (hu) |
| JP (1) | JP3025907B2 (hu) |
| KR (1) | KR100227231B1 (hu) |
| CN (1) | CN1068000C (hu) |
| AP (1) | AP779A (hu) |
| AT (1) | ATE198889T1 (hu) |
| AU (1) | AU697744C (hu) |
| BG (1) | BG63694B1 (hu) |
| BR (1) | BR9509436A (hu) |
| CA (1) | CA2203274C (hu) |
| CY (1) | CY2256B1 (hu) |
| CZ (1) | CZ286476B6 (hu) |
| DE (3) | DE69519995T2 (hu) |
| DK (1) | DK0788496T3 (hu) |
| ES (1) | ES2155535T3 (hu) |
| FI (1) | FI119548B (hu) |
| GR (1) | GR3035519T3 (hu) |
| HR (1) | HRP950532B1 (hu) |
| HU (1) | HU219862B (hu) |
| IL (1) | IL115771A (hu) |
| LU (1) | LU91306I2 (hu) |
| NO (1) | NO311937B1 (hu) |
| NZ (1) | NZ295353A (hu) |
| OA (1) | OA10479A (hu) |
| PT (1) | PT788496E (hu) |
| RO (1) | RO118715B1 (hu) |
| SK (1) | SK281908B6 (hu) |
| TR (1) | TR199501295A2 (hu) |
| WO (1) | WO1996013499A1 (hu) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EE200000186A (et) * | 1997-11-03 | 2001-04-16 | Janssen Pharmaceutica N.V. | Osake, selliste osakeste valmistamismeetod ja kasutamine, farmatseutiline doosivorm ja selle valmistamismeetod, tahke dispersioon ja farmatseutiline pakend |
| PL358909A1 (en) * | 1998-04-27 | 2004-08-23 | Janssen Pharmaceutica N.V. | Pellets having a core coated with a lipid lowering agent and a polymer |
| ES2195653T3 (es) * | 1998-12-22 | 2003-12-01 | Janssen Pharmaceutica Nv | Compuesto de s-oxido que disminuyen los lipidos. |
| DE19945982A1 (de) * | 1999-09-24 | 2001-03-29 | Knoll Ag | Geschwindigkeitsbestimmte Partikel |
| US20050132022A1 (en) * | 2003-12-12 | 2005-06-16 | International Business Machines Corporation | Computer system with LAN-based I/O |
| AU2005205933B2 (en) * | 2004-01-21 | 2010-02-18 | Elanco Animal Health Ireland Limited | Mitratapide oral solution |
| US7649002B2 (en) | 2004-02-04 | 2010-01-19 | Pfizer Inc | (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists |
| US7262318B2 (en) * | 2004-03-10 | 2007-08-28 | Pfizer, Inc. | Substituted heteroaryl- and phenylsulfamoyl compounds |
| AU2005230397B2 (en) * | 2004-04-09 | 2010-04-08 | Elanco Animal Health Ireland Limited | Intermittent dosing regimen for the treatment of overweight with MTP-inhibitors |
| US20050288340A1 (en) * | 2004-06-29 | 2005-12-29 | Pfizer Inc | Substituted heteroaryl- and phenylsulfamoyl compounds |
| PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
| WO2006129193A2 (en) * | 2005-05-27 | 2006-12-07 | Pfizer Products Inc. | Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss |
| JP2009503050A (ja) * | 2005-08-04 | 2009-01-29 | ファイザー・リミテッド | ピペリジノイル−ピロリジンおよびピペリジノイル−ピペリジン化合物 |
| US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
| US7888376B2 (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
| AU2007219236B2 (en) * | 2006-02-23 | 2012-06-21 | Pfizer Limited | Melanocortin type 4 receptor agonist piperidinoylpyrrolidines |
| US8383660B2 (en) | 2006-03-10 | 2013-02-26 | Pfizer Inc. | Dibenzyl amine compounds and derivatives |
| JP2010509392A (ja) | 2006-11-13 | 2010-03-25 | ファイザー・プロダクツ・インク | ジアリール、ジピリジニルおよびアリール−ピリジニル誘導体ならびにその使用 |
| CN101663262B (zh) | 2006-12-01 | 2014-03-26 | 百时美施贵宝公司 | 用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物 |
| ES2348530T3 (es) * | 2007-05-25 | 2010-12-09 | Janssen Pharmaceutica, N.V. | Síntesis mejorada de metanosulfonato de (2s-cis)-2-(bromometil)-2-(4-clorofenil)-1,3 dioxolan-4-metanol (éster). |
| DK2326638T5 (da) * | 2008-08-06 | 2014-01-13 | Pfizer Ltd | Diazepin- og diazocan-forbindelser som mc4-agonister |
| AU2011254654B2 (en) * | 2010-05-19 | 2016-01-07 | Sandoz Ag | Process for the preparation of chiral triazolones |
| HUE057970T2 (hu) | 2018-03-08 | 2022-06-28 | Incyte Corp | Aminopirazindiol-vegyületek mint PI3K-Y inhibitorok |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4267179A (en) * | 1978-06-23 | 1981-05-12 | Janssen Pharmaceutica, N.V. | Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles |
| US4313953A (en) * | 1978-06-23 | 1982-02-02 | Janssen Pharmaceutica, N.V. | Heterocyclic derivatives of (4-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles |
| US4766125A (en) * | 1981-06-23 | 1988-08-23 | Janssen Pharmaceutica N.V. | N-aryl-piperazinealkanamides useful for protecting hearts from myocardial injury caused by ischaemia, anoxia or hypoxia |
| US4619931A (en) * | 1983-02-28 | 1986-10-28 | Janssen Pharmaceutica, N.V. | [[4-[4-(4-phenyl-1-piperazinyl)phenoxymethyl]-1,3-dioxolan-2-yl]methyl]-1H-imidazoles and 1H-1,2,4-triazoles |
| CA1292472C (en) * | 1985-12-03 | 1991-11-26 | Alfonsus Guilielmus Knaeps | Derivatives of ¬¬4-¬4-(4-phenyl-1-piperazinyl)- phenoxymethyl|-1,3-dioxolan-2-yl|methyl|-1h-imidazoles and 1h-1,2,4-triazoles |
| NZ223799A (en) * | 1987-03-25 | 1989-12-21 | Janssen Pharmaceutica Nv | Azolylmethyl-dioxolanylmethoxyphenyl-piperazinyl-phenyl-triazolones and antimicrobial compositions |
| CA1331757C (en) * | 1988-02-29 | 1994-08-30 | Janssen Pharmaceutica Naamloze Vennootschap | 5-lipoxygenase inhibiting 4-(4-phenyl-1-piperazinyl)phenols |
| AU6359594A (en) * | 1993-03-04 | 1994-09-26 | Cytoven International N.V. | Pharmaceutical tryptophan containing dipeptide compositions and methods of use thereof |
| US5521186A (en) * | 1994-10-27 | 1996-05-28 | Janssen Pharmaceutica N.V. | Apolipoprotein-β synthesis inhibitors |
-
1995
- 1995-10-19 DK DK95937804T patent/DK0788496T3/da active
- 1995-10-19 ES ES95937804T patent/ES2155535T3/es not_active Expired - Lifetime
- 1995-10-19 CZ CZ19971198A patent/CZ286476B6/cs not_active IP Right Cessation
- 1995-10-19 DE DE69519995T patent/DE69519995T2/de not_active Expired - Lifetime
- 1995-10-19 AP APAP/P/1997/000968A patent/AP779A/en active
- 1995-10-19 WO PCT/EP1995/004111 patent/WO1996013499A1/en active IP Right Grant
- 1995-10-19 JP JP8514288A patent/JP3025907B2/ja not_active Expired - Fee Related
- 1995-10-19 NZ NZ295353A patent/NZ295353A/en not_active IP Right Cessation
- 1995-10-19 AU AU38680/95A patent/AU697744C/en not_active Ceased
- 1995-10-19 BR BR9509436A patent/BR9509436A/pt not_active IP Right Cessation
- 1995-10-19 HU HU9701956A patent/HU219862B/hu not_active IP Right Cessation
- 1995-10-19 AT AT95937804T patent/ATE198889T1/de active
- 1995-10-19 EP EP95937804A patent/EP0788496B1/en not_active Expired - Lifetime
- 1995-10-19 CN CN95195885A patent/CN1068000C/zh not_active Expired - Fee Related
- 1995-10-19 RO RO97-00812A patent/RO118715B1/ro unknown
- 1995-10-19 SK SK507-97A patent/SK281908B6/sk not_active IP Right Cessation
- 1995-10-19 PT PT95937804T patent/PT788496E/pt unknown
- 1995-10-19 CA CA002203274A patent/CA2203274C/en not_active Expired - Fee Related
- 1995-10-19 DE DE1995619995 patent/DE122007000005I1/de active Pending
- 1995-10-19 DE DE122007000005C patent/DE122007000005I2/de active Active
- 1995-10-19 US US08/817,247 patent/US5929075A/en not_active Expired - Lifetime
- 1995-10-19 KR KR1019970702662A patent/KR100227231B1/ko not_active IP Right Cessation
- 1995-10-20 TR TR95/01295A patent/TR199501295A2/xx unknown
- 1995-10-26 IL IL11577195A patent/IL115771A/xx not_active IP Right Cessation
- 1995-10-27 HR HR950532A patent/HRP950532B1/xx not_active IP Right Cessation
-
1997
- 1997-04-10 BG BG101402A patent/BG63694B1/bg unknown
- 1997-04-24 NO NO19971895A patent/NO311937B1/no not_active IP Right Cessation
- 1997-04-25 OA OA60997A patent/OA10479A/en unknown
- 1997-04-25 FI FI971784A patent/FI119548B/fi not_active IP Right Cessation
-
2001
- 2001-03-05 GR GR20010400359T patent/GR3035519T3/el unknown
-
2002
- 2002-01-04 CY CY0200004A patent/CY2256B1/xx unknown
-
2007
- 2007-01-17 LU LU91306C patent/LU91306I2/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2256B1 (en) | Apolipoprotein-b synthesis inhibitors | |
| PL321759A1 (en) | Novel thrombosin inhibitors | |
| EP0835109A4 (en) | PYRIDINONE-BASED THROMBIN INHIBITORS | |
| GB9511694D0 (en) | Benzamide derivatives | |
| GB9511935D0 (en) | Novel compound | |
| ZA959084B (en) | Apolipoprotein-b synthesis inhibitors | |
| HU9503783D0 (en) | Squvalen syntetase inhibitors | |
| DE69523450D1 (en) | Inhibitor | |
| GB9413710D0 (en) | Chiral synthesis | |
| SG49610A1 (en) | Novel inhibitor | |
| GB9522007D0 (en) | New compound | |
| EP0747449A4 (en) | BISAZO CONNECTION | |
| ZA9610588B (en) | Diamond synthesis | |
| GB9504868D0 (en) | Benzamide derivatives | |
| GB9504366D0 (en) | Benzamide derivatives | |
| ZA981321B (en) | Novel use of azoles | |
| GB9516647D0 (en) | New compound | |
| GB9508826D0 (en) | New Compound | |
| GB9512964D0 (en) | New compound | |
| GB9512972D0 (en) | New compound | |
| GB9505437D0 (en) | New compound | |
| GB9515162D0 (en) | New compound | |
| GB9508745D0 (en) | New compound | |
| GB9524266D0 (en) | New compound | |
| GB9507254D0 (en) | New compound |